388 related articles for article (PubMed ID: 28767209)
21. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
22. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Hatta K; Kishi Y; Wada K; Takeuchi T; Hashimoto N; Suda K; Taira T; Tsuchida K; Ohmori T; Akizuki N; Nishio Y; Nakanishi Y; Usui C; Kurata A; Horikawa N; Eguchi H; Ito S; Muto H; Nakamura H; Uchimura N
J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851436
[TBL] [Abstract][Full Text] [Related]
23. Suvorexant-Induced Delirium.
Yoshida K; Nakamura K; Yasui-Furukori N
Prim Care Companion CNS Disord; 2018 Nov; 20(6):. PubMed ID: 30476370
[No Abstract] [Full Text] [Related]
24. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-controlled clinical trial.
Schrijver EJ; de Vries OJ; Verburg A; de Graaf K; Bet PM; van de Ven PM; Kamper AM; Diepeveen SH; Anten S; Siegel A; Kuipéri E; Lagaay AM; van Marum RJ; van Strien AM; Boelaarts L; Pons D; Kramer MH; Nanayakkara PW
BMC Geriatr; 2014 Aug; 14():96. PubMed ID: 25168927
[TBL] [Abstract][Full Text] [Related]
27. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
Hamuro A; Honda M; Wakaura Y
Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
[No Abstract] [Full Text] [Related]
28. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
[TBL] [Abstract][Full Text] [Related]
29. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
30. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
[TBL] [Abstract][Full Text] [Related]
31. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study.
Matsuoka A; Sogawa R; Murakawa-Hirachi T; Mizoguchi Y; Monji A; Shimanoe C; Shinada K; Koami H; Sakamoto Y
Gen Hosp Psychiatry; 2023; 83():123-129. PubMed ID: 37182281
[TBL] [Abstract][Full Text] [Related]
33. Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials.
Shiga T; Hoshino H; Ochiai H; Osakabe Y; Kanno K; Horikoshi S; Miura I; Yabe H
J Psychopharmacol; 2021 Dec; 35(12):1488-1495. PubMed ID: 34330170
[TBL] [Abstract][Full Text] [Related]
34. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
35. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Vermeeren A; Sun H; Vuurman EF; Jongen S; Van Leeuwen CJ; Van Oers AC; Palcza J; Li X; Laethem T; Heirman I; Bautmans A; Troyer MD; Wrishko R; McCrea J
Sleep; 2015 Nov; 38(11):1803-13. PubMed ID: 26039969
[TBL] [Abstract][Full Text] [Related]
36. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
37. Suvorexant for the prevention of delirium: A meta-analysis.
Xu S; Cui Y; Shen J; Wang P
Medicine (Baltimore); 2020 Jul; 99(30):e21043. PubMed ID: 32791676
[TBL] [Abstract][Full Text] [Related]
38. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial.
Azuma K; Takaesu Y; Soeda H; Iguchi A; Uchida K; Ohta S; Mishima S; Inoue T; Inoue Y; Oda J
Acute Med Surg; 2018 Oct; 5(4):362-368. PubMed ID: 30338083
[TBL] [Abstract][Full Text] [Related]
39. [Usefulness of Suvorexant for Complicated Delirium in Cancer Patients Who Experience Sleep Disturbance during Hospitalization].
Kessoku T; Kusakabe A; Matsuura T; Honda Y; Yoshimi A; Goto A; Yoshida H; Sukegawa A; Hata C; Saito Y; Miyashita Y; Yashiro R; Komori T; Arai S; Nakajima A; Ichikawa Y
Gan To Kagaku Ryoho; 2018 Mar; 45(Suppl 1):92-94. PubMed ID: 29650886
[TBL] [Abstract][Full Text] [Related]
40. Distinct effects of orexin receptor antagonist and GABA
Seol J; Fujii Y; Park I; Suzuki Y; Kawana F; Yajima K; Fukusumi S; Okura T; Satoh M; Tokuyama K; Kokubo T; Yanagisawa M
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24353-24358. PubMed ID: 31712421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
